IGF-I levels and depressive disorders: Results from the Study of Health in Pomerania (SHIP)

Sievers, Caroline; Auer, Matthias; Athanasoulia, AP; Schneider, Harald J.; Nauck, Matthias; Völzke, Henry; John, Ulrich; Schulz, Andrea; Freyberger, H. J.; Friedrich, Nele; Biffar, Reiner; Stalla, Günter; Wallaschofski, Henri; Grabe, Hans‐Jörgen

doi:10.1016/j.euroneuro.2014.01.008

Cited by 33 publications

(42 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the SHIP-study, low baseline IGF-1 concentrations in females and high baseline IGF-1 concentrations in males predicted the development of any depressive disorder over time (Sievers et al, 2014). These longitudinal associations were not observed in the present study, which may be due to several differences.…”

Section: Discussioncontrasting

confidence: 81%

“…In contrast, in a recent epidemiological study investigating the association between IGF-1 and any depressive disorder, the Study of Health in Pomerania (SHIP), no cross-sectional associations were observed between IGF-1 and any depressive disorder (Sievers et al, 2014). Although possible explanations remain elusive, altered functioning of the GH-IGF-1 axis, with hypo-as well as hypersecretion being reported, has been suggested during depression (Mendlewicz et al, 1985;Voderholzer et al, 1993).…”

Section: Discussionmentioning

confidence: 82%

“…Differences between the two genders have also been observed in studies exploring depression, the GH-IGF-1 axis in elderly or the effects of GH replacement therapy in GHD or healthy adults (Beekman et al, 1999;Burman et al, 1997;Munzer et al, 2009;van Bunderen et al, 2013). In the previously mentioned SHIP-study, sex differences were also evident (Sievers et al, 2014). Whether these differences may be caused by variations across gender in sex hormones or GH-and IGF-1-binding protein levels, as has been hypothesized, still remains uncertain.…”

Section: Discussionmentioning

confidence: 85%

“…Nevertheless, only few studies with limited sample sizes and no or short follow-up time have addressed the relation between IGF-1 and depression in humans (Deuschle et al, 1997;Franz et al, 1999;Lesch et al, 1988aLesch et al, , 1988bRupprecht et al, 1989;Schilling et al, 2011;Weber-Hamann et al, 2009). So far, only one epidemiological study has been reported, in which lower IGF-1 concentrations were associated with any depressive disorder in women, while higher IGF-1 concentrations were associated with any depressive disorder in men (Sievers et al, 2014). However, in this study only a screening self-report questionnaire was used for the assessment of any depressive disorder, which complicates interpretation of the results.…”

Section: Introductionmentioning

confidence: 90%

See 3 more Smart Citations

Serum insulin-like growth factor 1 and late-life depression: A population-based study

Varsseveld

Bunderen

Sohl

et al. 2015

Psychoneuroendocrinology

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 81%

Section: Discussionmentioning

confidence: 82%

Section: Discussionmentioning

confidence: 85%

Section: Introductionmentioning

confidence: 90%

See 2 more Smart Citations

Serum insulin-like growth factor 1 and late-life depression: A population-based study

Varsseveld

Bunderen

Sohl

et al. 2015

Psychoneuroendocrinology

View full text Add to dashboard Cite

“…Neurotrophins regulate neurogenesis in the hippocampus. Levels of several neurotrophins are altered in MDD, including BDNF [160], vascular endothelial growth factor [161], insulin growth factor [162], NT-3 [163], fibroblast growth factors [164], S100 calcium binding protein B (S100B) [165,166], and glial cell line-derived neurotrophic factor (GNDF) [167]. BDNF is nevertheless the most studied neurotrophin in MDD.…”

Section: Bdnf and Other Neurotrophinsmentioning

confidence: 99%

Cognitive Dysfunction in Depression – Pathophysiology and Novel Targets

Carvalho¹,

Miskowiak²,

Hyphantis³

et al. 2015

CNSNDDT

View full text Add to dashboard Cite

Major depressive disorder (MDD) is associated with cognitive dysfunction encompassing several domains, including memory, executive function, processing speed and attention. Cognitive deficits persist in a significant proportion of patients even in remission, compromising psychosocial functioning and workforce performance. While monoaminergic antidepressants may improve cognitive performance in MDD, most antidepressants have limited clinical efficacy. The overarching aims of this review were: (1) to synthesize extant literature on putative biological pathways related to cognitive dysfunction in MDD and (2) to review novel neurotherapeutic targets for cognitive enhancement in MDD. We found that reciprocal and overlapping biological pathways may contribute to cognitive dysfunction in MDD, including an hyperactive hypothalamic-pituitary-adrenal axis, an increase in oxidative and nitrosative stress, inflammation (e.g., enhanced production of pro-inflammatory cytokines), mitochondrial dysfunction, increased apoptosis as well as a diminished neurotrophic support. Several promising neurotherapeutic targets were identified such as minocycline, statins, anti-inflammatory compounds, N-acetylcysteine, omega-3 poliunsaturated fatty acids, erythropoietin, thiazolidinediones, glucagon-like peptide-1 analogues, S-adenosyl-l-methionine (SAMe), cocoa flavonols, creatine monohydrate and lithium. Erythropoietin and SAMe had pro-cognitive effects in randomized controlled trials (RCT) involving MDD patients. Despite having preclinical and/or preliminary evidences from trials suggesting possible efficacy as novel cognitive enhancing agents for MDD, no RCT to date was performed for most of the other therapeutic targets reviewed herein. In conclusion, multiple biological pathways are involved in cognitive dysfunction in MDD. RCTs testing genuinely novel pro-cognitive compounds for MDD are warranted.

show abstract

Impact of chronic disease on emotional distress in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study

Vuotto

Krull

et al. 2016

Cancer

View full text Add to dashboard Cite

Author contributions:Vuotto: conception and design; analysis and interpretation of data; drafting the article and revising it critically for important intellectual content; final approval of the version to be published Krull: conception and design; analysis and interpretation of data; drafting the article and revising it critically for important intellectual content; final approval of the version to be published Li: analysis and interpretation of data; revising the article for critically for important intellectual content; final approval of the version to be published Oeffinger: conception and design; acquisition of data; drafting the article and revising it critically for important intellectual content; final approval of the version to be published Green: conception and design; acquisition of data; revising the article for critically for important intellectual content; final approval of the version to be published Patel: conception and design; revising the article for critically for important intellectual content; final approval of the version to be published Srivastava: analysis and interpretation of data; revising the article for critically for important intellectual content; final approval of the version to be published Stovall: conception and design; acquisition of data; revising the article for critically for important intellectual content; final approval of the version to be published Ness: conception and design; revising the article for critically for important intellectual content; final approval of the version to be published Armstrong: conception and design; revising the article for critically for important intellectual content; final approval of the version to be published; funding acquisition Robison: conception and design; acquisition of data; revising the article for critically for important intellectual content; final approval of the version to be published; funding acquisition Brinkman: conception and design; analysis and interpretation of data; drafting the article and revising it critically for important intellectual content; final approval of the version to be published Dr. Brinkman is responsible for the overall content of the article. Conclusions-Chronic health conditions resulting from childhood cancer therapies contribute to emotional distress in adult survivors. Targeted mental health screening efforts in this at-risk population appear warranted. Therapeutic approaches should consider the complex interplay between chronic health conditions and symptoms of emotional distress. HHS Public Access Graphical AbstractPrecis: Survivors who have been exposed to cancer directed therapies in childhood are at increased risk for developing cardiac, endocrine and pulmonary chronic health conditions. These chronic health conditions contribute to emotional distress symptoms in adult survivors of childhood cancer.

show abstract

IGF-I levels and depressive disorders: Results from the Study of Health in Pomerania (SHIP)

Cited by 33 publications

References 33 publications

Serum insulin-like growth factor 1 and late-life depression: A population-based study

Serum insulin-like growth factor 1 and late-life depression: A population-based study

Cognitive Dysfunction in Depression – Pathophysiology and Novel Targets

Impact of chronic disease on emotional distress in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study

Contact Info

Product

Resources

About